» Articles » PMID: 16945958

Competition for RISC Binding Predicts in Vitro Potency of SiRNA

Overview
Specialty Biochemistry
Date 2006 Sep 2
PMID 16945958
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Short interfering RNAs (siRNA) guide degradation of target RNA by the RNA-induced silencing complex (RISC). The use of siRNA in animals is limited partially due to the short half-life of siRNAs in tissues. Chemically modified siRNAs are necessary that maintain mRNA degradation activity, but are more stable to nucleases. In this study, we utilized alternating 2'-O-methyl and 2'-deoxy-2'-fluoro (OMe/F) chemically modified siRNA targeting PTEN and Eg5. OMe/F-modified siRNA consistently reduced mRNA and protein levels with equal or greater potency and efficacy than unmodified siRNA. We showed that modified siRNAs use the RISC mechanism and lead to cleavage of target mRNA at the same position as unmodified siRNA. We further demonstrated that siRNAs can compete with each other, where highly potent siRNAs can compete with less potent siRNAs, thus limiting the ability of siRNAs with lower potency to mediate mRNA degradation. In contrast, a siRNA with low potency cannot compete with a highly efficient siRNA. We established a correlation between siRNA potency and ability to compete with other siRNAs. Thus, siRNAs that are more potent inhibitors for mRNA destruction have the potential to out-compete less potent siRNAs indicating that the amount of a cellular component, perhaps RISC, limits siRNA activity.

Citing Articles

Advances and prospects of RNA delivery nanoplatforms for cancer therapy.

Attia M, Kijanka G, Nguyen N, Zhang J, An H Acta Pharm Sin B. 2025; 15(1):52-96.

PMID: 40041887 PMC: 11873661. DOI: 10.1016/j.apsb.2024.09.009.


A highly sensitive stem-loop RT-qPCR method to study siRNA intracellular pharmacokinetics and pharmacodynamics.

Chen L, Bosmajian C, Woo S Biol Methods Protoc. 2024; 9(1):bpae029.

PMID: 38783988 PMC: 11112049. DOI: 10.1093/biomethods/bpae029.


Oligonucleotide therapies for nonalcoholic steatohepatitis.

Li S, Xiong F, Zhang S, Liu J, Gao G, Xie J Mol Ther Nucleic Acids. 2024; 35(2):102184.

PMID: 38665220 PMC: 11044058. DOI: 10.1016/j.omtn.2024.102184.


A global genetic interaction network by single-cell imaging and machine learning.

Heigwer F, Scheeder C, Bageritz J, Yousefian S, Rauscher B, Laufer C Cell Syst. 2023; 14(5):346-362.e6.

PMID: 37116498 PMC: 10206407. DOI: 10.1016/j.cels.2023.03.003.


Cheminformatics Modeling of Gene Silencing for Both Natural and Chemically Modified siRNAs.

Dong X, Zheng W Molecules. 2022; 27(19).

PMID: 36234948 PMC: 9570765. DOI: 10.3390/molecules27196412.


References
1.
Tuschl T, Zamore P, Lehmann R, Bartel D, Sharp P . Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev. 2000; 13(24):3191-7. PMC: 317199. DOI: 10.1101/gad.13.24.3191. View

2.
Grimm D, Streetz K, Jopling C, Storm T, Pandey K, Davis C . Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006; 441(7092):537-41. DOI: 10.1038/nature04791. View

3.
McManus M, Haines B, Dillon C, Whitehurst C, Van Parijs L, Chen J . Small interfering RNA-mediated gene silencing in T lymphocytes. J Immunol. 2002; 169(10):5754-60. DOI: 10.4049/jimmunol.169.10.5754. View

4.
Amarzguioui M, Holen T, Babaie E, Prydz H . Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003; 31(2):589-95. PMC: 140512. DOI: 10.1093/nar/gkg147. View

5.
Holen T, Amarzguioui M, Babaie E, Prydz H . Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res. 2003; 31(9):2401-7. PMC: 154224. DOI: 10.1093/nar/gkg338. View